On human tissue kallikrein activity in urine of Brazilian white and black primary hypertensive patients

Ethnicity and Disease

Volumn 19, Issue 3, 2009, Pages 265-270

  Belo, Andreza Alves ^a   Sousa, Marinez De Oliveira ^a   Machado, Eduardo Luis Guimarães ^b   Figueiredo, Amintas Fabiano De Souza ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Faculdade de Ciencias Medicas de Minas Gerais   (Brazil)

Author keywords

Brazilian; Ethnic groups; Human kallikrein; Human tissue kallikrein; Hypertension

Indexed keywords

4 NITROANILIDE; ANILIDE; CREATININE; TISSUE KALLIKREIN; TISSUE KALLIKREIN AMIDASE; UNCLASSIFIED DRUG; AMIDASE;

ADULT; AFRICAN AMERICAN; ARTICLE; BRAZILIAN WHITE; CAUCASIAN; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROTEIN FUNCTION; PROTEIN URINE LEVEL; SEX DIFFERENCE; URINE; URINE FLOW RATE; BRAZIL; CASE CONTROL STUDY; ENZYMOLOGY; ETHNOLOGY; MIDDLE AGED; NEGRO; STATISTICS;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AMIDOHYDROLASES; BRAZIL; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SEX FACTORS; TISSUE KALLIKREINS;

EID: 70349772252     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Song CK, Martinez JA, Kailasam MT, Dao TT, Wong CM, Parmer RJ. Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension. J Hum Hypertens. 2000;14:461-468.
2. Krieger JE, Dzau VJ. Molecular biology of hypertension. Hypertension. 1991;18(Suppl I):I-3-I-17.
3. Sun Z, Zhang Z. Historic perspectives and recent advances in major animal models of hypertension. Acta Pharmacol Sin. 2005;26:295-301. (Pubitemid 40388064)
4. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev. 1992;44:1-80.
5. Yousef GM, Diamandis EP. Tissue kallikreins: new players in normal and abnormal cell growth? Thromb Haemost. 2003;90:7-16.
6. MacDonald RJ, Margolius HS, Erdös EG. Molecular biology of tissue kallikrein. Biochem J. 1988;253:313-321.
7. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol. 2001;28:1060-1065.
8. Wong CM, O'Connor DT, Martinez JA, Kailasam MT, Parmer RJ. Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinats of an intermediate phenotype for hypertension. Am J Hypertens. 2003;16:281-289.
9. Seedat YK, Bhoola KD, Muller R, Randeree IGH, Pillay D. Urinary levels of tissue kallikrein in the South African Black and Indian hypertensives. J Hum Hypertens. 1999;13:771-775. (Pubitemid 29533010)
10. Brazilian Institute of Geography and Statistics (IBGE). Available at http://www.ibge.gov.br. Last accessed 5/26/09.
11. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci. 2003;100:177-182.
12. Erlanger BF, Kokowsky N, Cohen W. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys. 1961;95:271-278.
13. Geiger R, Fritz H. Human urinary kallikrein. Methods Enzymol. 1981;80:466-492.
14. Figueiredo EL, Leão FVG, Oliveira LV, Moreira MCV, Figueiredo AFS. The amidase activity of human tissue kallikrein is significantly lower in the urine of patients with systolic heart failure. J Card Fail. 2006;12:653-658.
15. Elliot R, Nuzum F. Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology. 1934;18:462-474.
16. MargoliusHS, Geller R, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet. 1971;2:1063-1065.
17. O'Connor DT. Response of renal kallikreinkinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension. 1982;4(Suppl):III-72-III-78.
18. Margolius HS. Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension. 1995;26:221-229.
19. Chao J, Shigemichi T, Margolius HS. Inhibitory effects of sodium and other monovalent cations on purified versus membrane- bound kallikrein. J Biol Chem. 1983;258:6461-6465. (Pubitemid 13106820)
20. Sousa MO, Santoro MM, Figueiredo AFS. The effect of cations on the amidase activity of human tissue kallikrein: 1 - linear competitive inhibition by sodium, potassium, calcium and magnesium. 2 - Linear mixed inhibition by aluminium. J Enz Inh Med Chem. 2004;19:317-325.
21. Johnson AM. Amino acids, peptides, and proteins. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. St. Louis: Elsevier Saunders, 2006;533-595.
22. Ash KO, Smith JB, Lynch M, Dadone M, Tolman KG, Williams RR. Urinary kallikrein: assay validation and physiological variability. Clin Chim Acta. 1985;151:133-140. (Pubitemid 15248320)
23. Huges Jr. GS, Margolius HS, Peters R, Oexmann MJ, Chao J, Lindenmayer G. Gender differences of tissue kallikrein and an erythrocyte kallikrein-like enzyme in essential hypertension. J Lab Clin Med. 1988;112:612-618. (Pubitemid 19006794)
24. Lieberthal W, Arbeit L, Oza NB, Bernard DB, Levinsky NG. Reduced ratio of active-to-total urinary kallikrein in essential hypertension. Hypertension. 1983;5:603-609. (Pubitemid 13076703)
25. Katori M, Majima M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol. 1996;70:95-128. (Pubitemid 26079782)